Autosomal Recessive Spinocerebellar Ataxia 12 (SCAR12),

Autosomal recessive spinocerebellar ataxia 12 (SCAR12) is a very rare, inherited brain disorder. Children with SCAR12 usually start having generalized seizures in infancy, followed by delayed motor and language milestones, learning difficulties, and cerebellar ataxia—that means poor balance, shaky movements, and trouble with coordination. Many children also have slurred speech (dysarthria) and jerky eye movements (gaze-evoked nystagmus). In some families, doctors also see spasticity (stiff, tight muscles) and upper motor neuron signs like brisk reflexes or an up-going plantar response. Brain MRI may be normal early on or show mild cerebellar atrophy. SCAR12 happens when a child inherits two faulty copies of the WWOX gene (one from each parent). This gene helps brain cells signal properly; when it does not work, circuits that fine-tune movement and control seizures are affected. NCBI+2rarediseases.info.nih.gov+2

SCAR12 is a genetic condition that a child inherits from both parents, each carrying one silent copy of the faulty gene. Most children show unsteady walking (ataxia) in early childhood, and many also have generalized seizures, speech difficulty, and slow learning. Some develop leg stiffness (spasticity) and nystagmus. Brain MRI may show mild cerebellar atrophy. The most commonly implicated gene is WWOX, which helps brain cells handle stress and survive; when it does not work well, brain circuits that control balance, movement, and learning can be affected. SCAR12 is different from SCA12 (PPP2R2B expansion, autosomal dominant, adult onset). orpha.net+3ncbi.nlm.nih.gov+3informatics.jax.org+3

Genetically, SCAR12 sits on a WWOX-related disease spectrum. Biallelic missense (hypomorphic) variants in WWOX are typically linked with the milder SCAR12 phenotype, while biallelic null variants often cause WOREE (WWOX-related developmental and epileptic encephalopathy), which is far more severe and can be fatal early in life. Some patients with one missense and one loss-of-function allele show features in-between. PMC

The first families with SCAR12 were mapped to chromosome 16q21–q23 and later shown to carry WWOX mutations (for example, p.Pro47Thr and p.Gly372Arg). These changes disrupt WWOX structure and interactions, leading to the clinical picture of seizures, intellectual disability, and ataxia. NCBI+3PubMed+3PMC+3

---

Other names

• SCAR12 (spinocerebellar ataxia, autosomal recessive 12)

• Autosomal recessive cerebellar ataxia–epilepsy–intellectual disability syndrome due to WWOX deficiency

• Spinocerebellar ataxia with mental retardation and epilepsy (historical wording used in early reports)

• Disease ontology and registries may list: MONDO:0013687, OMIM:614322, Orphanet:284282. monarchinitiative.org+1

---

Types

Although “SCAR12” is a single diagnosis, clinicians often describe clinical subtypes along a WWOX spectrum:

1. Classic SCAR12 – infancy-onset seizures, developmental delay, cerebellar ataxia; usually due to biallelic missense/hypomorphic WWOX variants; no reported early death in classic descriptions. PMC

2. Intermediate WWOX-related phenotype – features of SCAR12 with additional neurodevelopmental problems when one allele is severe (null) and the other is missense. PMC

3. WOREE syndrome (DEE-28) – severe developmental and epileptic encephalopathy, refractory seizures, frequent structural brain findings, and high early mortality; typically biallelic null variants. (Not SCAR12, but on the same gene spectrum.) Frontiers

These “types” are practical categories tied to genotype–phenotype correlation rather than formal numbered subtypes under SCAR12. PMC

---

Causes

1. Biallelic WWOX mutations (core cause). SCAR12 happens when both copies of the WWOX gene carry disease-causing variants. Without enough working WWOX protein, neurons cannot handle signals that control movement and seizures. PubMed

2. Missense (hypomorphic) variants. Many SCAR12 cases carry two missense changes that leave the protein partly active. This usually explains the milder course compared with WOREE. PMC

3. Pathogenic variants in conserved WW domain residues. Changes like p.Pro47Thr harm the WW domain structure and its protein–protein interactions, disturbing neuronal pathways that rely on those interactions. PubMed

4. Pathogenic variants in the SDR (dehydrogenase/reductase) domain. Variants such as p.Gly372Arg damage the catalytic region, reducing WWOX function and leading to the same clinical triad. NCBI

5. Compound heterozygosity (two different disease-causing variants). One allele may be a deletion and the other a missense change; together they lower WWOX activity below a safe threshold. PMC

6. Intronic or exon deletions affecting splicing. Structural variants that remove exons or disrupt splice sites reduce functional protein and can push patients toward SCAR12 or more severe disease. PMC

7. Frameshift or nonsense variants (when paired with milder alleles). If a truncating change is paired with a hypomorphic change, the phenotype may be intermediate but can include SCAR12-like features. PMC

8. Consanguinity (parents related by blood). This increases the chance that a child inherits the same rare WWOX variant from both parents and develops SCAR12. PubMed

9. Founder effects in specific populations. In some families or regions, a historical mutation may recur and cause clusters of cases. (Documented in early mapped families.) PubMed

10. WWOX pathway dysfunction in inhibitory circuits. Animal and cellular studies show WWOX loss impairs GABAergic inhibitory signaling, a mechanism that can promote seizures and motor incoordination. ScienceDirect

11. Abnormal neuronal network maturation. WWOX is active in developing brain; reduced function can alter synapse formation and circuit tuning, which later appears as ataxia and epilepsy. ScienceDirect

12. Cerebellar circuit vulnerability. The cerebellum coordinates movement; WWOX defects can make Purkinje and related pathways fragile, producing ataxia. (Supported by WWOX-related neurobiology.) ScienceDirect

13. Axonal and synaptic protein interaction loss. WW domains mediate protein–protein binding; when disrupted, downstream signaling in neurons is weakened. PubMed

14. Altered stress-response at fragile chromosomal sites. WWOX spans a common fragile site (FRA16D). Instability and reduced expression can contribute to neuronal dysfunction in WWOX disorders. GeneCards

15. Gene dosage below critical level. Two mild variants can still reduce function enough to cause disease, showing a threshold effect typical for recessive neurogenetic conditions. PMC

16. Developmental epileptic encephalopathy spectrum overlap. Shared mechanisms with WOREE (severe end) explain seizures in SCAR12, though expression is milder. Frontiers

17. Modifier genes. Differences between families with similar variants suggest other genes modify severity, shifting features within the WWOX spectrum. (Inferred from genotype–phenotype variability.) PMC

18. Environmental triggers lowering seizure threshold. Fever, sleep loss, or illness can unmask seizures in genetically vulnerable children, as in many epilepsies. (General epilepsy principle applied to SCAR12.) NCBI

19. Delayed myelination in severe WWOX disease. Severe WWOX loss shows delayed myelination; milder WWOX deficits in SCAR12 may share partial pathway effects that contribute to coordination problems. PMC

20. Loss of neuroprotective WWOX signaling. Experimental work suggests WWOX helps cell survival; reduced activity may increase neuron stress and vulnerability, adding to motor and cognitive symptoms. GeneCards

---

Symptoms and signs

1. Seizures starting in infancy. Most children have generalized seizures early in life. Seizures may be controlled with standard anti-seizure medicines in many SCAR12 cases. NCBI

2. Developmental delay. Sitting, standing, speaking, and learning often take longer to develop compared with peers. rarediseases.info.nih.gov

3. Intellectual disability or learning difficulties. School learning can be hard; extra educational support is commonly needed. NCBI

4. Cerebellar ataxia (poor balance and coordination). Children may wobble when walking, drop objects, or have shaky hand movements. rarediseases.info.nih.gov

5. Dysarthria (slurred speech). Speech can sound slow or shaky because muscles for speech are poorly coordinated. rarediseases.info.nih.gov

6. Gaze-evoked nystagmus. Eyes may make quick, jerky movements when looking to the side, a common cerebellar sign. rarediseases.info.nih.gov

7. Spasticity and brisk reflexes. Some children develop stiff legs and increased reflexes, pointing to upper motor neuron involvement. NCBI

8. Extensor plantar response (Babinski sign). The big toe may go up when the sole is stroked—a sign of pyramidal tract involvement reported in some families. rarediseases.info.nih.gov

9. Tremor or shaky movements. Fine tasks may be difficult, and hands may shake when reaching. (Cerebellar action tremor.) rarediseases.info.nih.gov

10. Gait instability and frequent falls. Walking can be wide-based and unsteady; children may fall more easily. rarediseases.info.nih.gov

11. Eye movement inaccuracy (dysmetria of saccades). Overshooting or undershooting targets when looking quickly can occur with cerebellar disease. rarediseases.info.nih.gov

12. Fatigability with tasks. Long activities that need steady control (writing, feeding) may be tiring. (Common in cerebellar ataxias.) www.elsevier.com

13. Mild cerebellar atrophy on MRI. Some children show shrinkage of cerebellar tissue on imaging, fitting the movement problems seen on exam. rarediseases.info.nih.gov

14. Behavioral or attention difficulties. Some reports note attention and executive challenges, likely secondary to the neurodevelopmental condition. NCBI

15. Speech and language delay. First words and sentence building often come late because of both motor speech and cognitive factors. rarediseases.info.nih.gov

---

Diagnostic tests

A) Physical examination (bedside neurologic and general exam)

1. General neurologic exam. A pediatric neurologist checks tone, strength, reflexes, sensation, and coordination to identify cerebellar signs and any pyramidal features. This first look guides further testing. www.elsevier.com

2. Gait assessment. Walking pattern is inspected for a wide-based, swaying gait typical of cerebellar ataxia; joint stiffness or scissoring suggests spasticity. www.elsevier.com

3. Ocular motor exam. The clinician looks for gaze-evoked nystagmus, saccade inaccuracy, or pursuit problems that support cerebellar involvement. rarediseases.info.nih.gov

4. Speech evaluation at bedside. Slurred, scanning speech suggests cerebellar dysarthria; this helps document functional impact. rarediseases.info.nih.gov

5. Developmental assessment. Age-appropriate screening of motor, language, and cognition establishes the child’s baseline and needs for therapy. rarediseases.info.nih.gov

B) Manual/bedside coordination tests (simple functional tasks)

6. Finger–nose–finger test. The child touches their nose and the examiner’s finger; overshoot and tremor point to cerebellar dysmetria. www.elsevier.com

7. Heel–knee–shin test. Sliding the heel down the opposite shin reveals leg dysmetria and helps grade severity. www.elsevier.com

8. Rapid alternating movements. Rapid hand flips (pronation–supination) show dysdiadochokinesia, a hallmark of cerebellar dysfunction. www.elsevier.com

9. Tandem (heel-to-toe) walking. Difficulty staying in a straight line supports truncal ataxia. www.elsevier.com

10. Romberg test (safely adapted for children). Increased sway with eyes closed suggests sensory or cerebellar imbalance; helps document postural control. www.elsevier.com

C) Laboratory and pathological tests

11. Targeted WWOX sequencing. Sequencing the WWOX gene identifies biallelic pathogenic variants and confirms SCAR12. Clinical labs also review variant databases such as ClinVar. NCBI

12. Exome or genome sequencing. When the diagnosis is unclear, broader sequencing finds WWOX variants or rules out other ataxia genes (APTX, SETX, PNKP, etc.) in the differential. PubMed

13. Copy-number analysis (exon-level CNV). MLPA or NGS CNV calling detects partial WWOX deletions/duplications that standard sequencing can miss. PMC

14. Variant segregation studies in parents. Testing parents shows each carries one variant (autosomal recessive pattern), strengthening the diagnosis. NCBI

15. Metabolic screening to exclude treatable ataxias. Basic labs (CBC, CMP), thyroid tests, vitamin E/B12, alpha-fetoprotein (for AOA types), and others help rule out alternative causes. (Good practice in ataxia workups.) www.elsevier.com

D) Electrodiagnostic tests

16. EEG (electroencephalogram). EEG documents seizure type, guides anti-seizure therapy, and may show generalized spikes or other epileptiform activity typical for infancy-onset epilepsies. NCBI

17. EMG/Nerve conduction studies (if neuropathy suspected). While neuropathy is not a core SCAR12 feature, testing is reasonable when weakness or sensory loss is noted, to eliminate other recessive ataxias with neuropathy. www.elsevier.com

E) Imaging tests

18. Brain MRI (structural). MRI may be normal early or show mild cerebellar atrophy; it also rules out other lesions. Serial scans help track progression. rarediseases.info.nih.gov

19. Quantitative volumetric MRI (when available). Research or specialized centers may measure cerebellar volume more precisely to document change over time in ataxias. (General ataxia imaging practice.) www.elsevier.com

20. Functional imaging (research settings). Advanced modalities (e.g., MR spectroscopy) can explore cerebellar metabolism in ataxia research; not needed for routine SCAR12 diagnosis. (Context from the recessive ataxia literature.) www.elsevier.com

Non-pharmacological treatments (therapies & others)

Note: there is no single best plan. Teams usually include neurology, physiatry, physical/occupational/speech therapy, nutrition, psychology, and social work. Goals are safety, function, comfort, and family support. rarediseases.info.nih.gov

1. Personalized physical therapy (PT)
   PT builds core strength, balance, posture, and endurance using task-oriented practice (gait, transfers, reaching), cueing, and fall-prevention drills. Programs often mix treadmill with harness support, overground balance work, and home exercises. Early, steady PT can slow secondary deconditioning and reduce falls, even if ataxia itself persists. Therapists also train safe mobility aids and caregiver techniques to reduce injury during seizures or spastic episodes. rarediseases.info.nih.gov

2. Occupational therapy (OT)
   OT focuses on daily living skills: dressing, feeding, writing, using devices, and school participation. Therapists adapt the environment (grab bars, seating, accessible desks), recommend weighted utensils, slant boards, and switch-access tools to reduce tremor/ataxia impact. They also teach energy conservation and break tasks into small, repeatable steps to build confidence and routine. rarediseases.info.nih.gov

3. Speech-language therapy
   Speech therapy addresses dysarthria (slow, slurred speech) and communication barriers. It trains breath support, pacing, and articulation, and introduces AAC (augmentative and alternative communication) when needed—ranging from picture boards to eye-gaze devices. Early intervention improves participation at home and school. rarediseases.info.nih.gov

4. Feeding and swallowing support
   Therapists assess oropharyngeal dysphagia and set safe textures, pacing, and posture. Techniques include chin-tuck, small controlled sips, and caregiver cueing. The goals are safety (prevent aspiration) and adequate calories for growth. Nutrition teams may use calorie-dense foods or supplements when weight gain lags. rarediseases.info.nih.gov

5. Spasticity rehabilitation program
   Stretching, splinting, serial casting, and task practice limit contractures and make walking or transfers easier. Programs coordinate with medications or injections (if used) and monitor function with simple measures (timed up-and-go, gait videos) to keep goals realistic and family-centered. rarediseases.info.nih.gov

6. Fall-prevention and home safety
   Plans cover lighting, clutter control, non-slip flooring, rails, and bathroom adaptations. Families learn how to recover from a fall safely and when to call for help after a seizure-related fall. Schools are advised about safe evacuation and supervision needs. rarediseases.info.nih.gov

7. Assistive mobility devices
   Depending on balance and endurance, options include ankle-foot orthoses, walkers, rollators, or wheelchairs for distance. Proper fitting lowers energy cost and reduces falls. As needs change, devices can be adjusted to maintain independence. rarediseases.info.nih.gov

8. Educational supports & individualized education plans (IEPs)
   Neurodevelopmental challenges in SCAR12 often require an IEP with classroom accommodations: preferential seating, extra time, breaks, assistive tech for writing/communication, and therapy minutes during school hours. Early advocacy improves outcomes. rarediseases.info.nih.gov

9. Behavioral and psychosocial support
   Families benefit from psychology and social work to cope with chronic care, coordinate services, and address anxiety/depression that can accompany neurologic disability. Support groups reduce isolation and teach problem-solving around daily hurdles. rarediseases.info.nih.gov

10. Seizure first-aid training for caregivers
    Caregivers learn positioning, timing, safety steps, and when to use rescue medication. Written action plans (home and school) ensure everyone knows what to do, which reduces ER visits and injuries. rarediseases.info.nih.gov

11. Nutrition optimization
    A dietitian helps maintain adequate calories, protein, fiber, and hydration, compensating for high energy expenditure from ataxia/spasticity and for any medication-related appetite changes. Regular growth monitoring is essential in children. rarediseases.info.nih.gov

12. Sleep hygiene
    Good sleep lowers seizure risk in many epilepsies. Routines include consistent bedtimes, quiet/dim rooms, limited screens, and addressing reflux or nighttime spasms that fragment sleep. rarediseases.info.nih.gov

13. Vision care
    Nystagmus and gaze issues affect reading and mobility. Regular ophthalmology checks, task lighting, and large-print or audio supports reduce strain and falls. rarediseases.info.nih.gov

14. Orthopedic monitoring
    Children with spasticity are screened for hip subluxation, scoliosis, and contractures. Early bracing or casting and seating adjustments can prevent painful deformities. rarediseases.info.nih.gov

15. Communication access at home
    Simple routines—slow pace, single-step directions, visual cues—make daily life smoother and reduce frustration for the child and caregivers. rarediseases.info.nih.gov

16. Emergency care plan
    Families keep a one-page summary with diagnosis, meds, rescue steps, and physician contacts for paramedics and ER teams. rarediseases.info.nih.gov

17. Vaccination and infection-prevention practices
    Routine vaccines and prompt treatment of fevers or respiratory infections help avoid seizure triggers and deconditioning from illness. rarediseases.info.nih.gov

18. Community and financial resource linkage
    Programs for transport, devices, and home modifications reduce burden and keep kids in school and activities. rarediseases.info.nih.gov

19. Genetic counseling
    Explains autosomal recessive inheritance: each future pregnancy has a 25% chance of being affected when both parents are carriers; offers testing options to relatives. informatics.jax.org

20. Clinical-trial awareness & registries
    Families can track natural-history studies and experimental therapies as they emerge in recessive ataxias and WWOX-related disorders; enrollment improves evidence for care. ScienceDirect

---

Drug treatments

Important: There is no FDA-approved disease-modifying drug for SCAR12. Medications manage seizures, spasticity, dystonia, sleep, reflux, and other symptoms. Labels below come from accessdata.fda.gov (FDA). Clinicians individualize choice and dosing.

• Levetiracetam – Broad-spectrum antiseizure medicine used for generalized tonic–clonic and focal seizures. Typically given twice daily and titrated for effect. Mechanism involves SV2A modulation, stabilizing neurotransmitter release; common effects: sleepiness, irritability. FDA labeling supports pediatric use in certain seizure types; in neurogenetic epilepsies it’s widely used off-label by mechanism and tolerability. rarediseases.info.nih.gov+1

• Valproate (divalproex/valproic acid) – Effective for many generalized seizures; mechanism: increases GABA, blocks sodium and T-type calcium channels. Requires liver and platelet monitoring; teratogenic—avoid in pregnancy and counsel adolescents. Often dosed 2–3 times daily or extended-release once daily. rarediseases.info.nih.gov

• Lamotrigine – Useful for generalized tonic–clonic and focal seizures; slow titration reduces rash risk. Mechanism: voltage-gated sodium channel inhibition; often twice daily dosing after titration. Can improve alertness relative to sedating agents. rarediseases.info.nih.gov

• Topiramate – Broad-spectrum with AMPA antagonism and carbonic anhydrase inhibition; helps generalized seizures; watch for cognitive slowing, weight loss, kidney stones; typically twice daily. rarediseases.info.nih.gov

• Clobazam – Benzodiazepine for adjunctive seizure control; enhances GABA-A. Often improves drop seizures and generalized seizures but can cause sedation and tolerance. Dosed once or twice daily. rarediseases.info.nih.gov

• Diazepam rectal gel or nasal sprays (rescue) – For acute prolonged seizures/cluster seizures at home or school; rapid GABA-A potentiation; main risks: sedation, respiratory depression if overused. Clear action plans reduce ER visits. rarediseases.info.nih.gov

• Baclofen (oral) – For spasticity; GABA-B agonist reduces spinal reflex hyperexcitability; dose slowly to limit sleepiness/weakness; do not stop abruptly. rarediseases.info.nih.gov

• Tizanidine – Alpha-2 adrenergic agonist for spasticity; short-acting; watch hypotension and sleepiness; titrate to activities (e.g., evenings). rarediseases.info.nih.gov

• Botulinum toxin injections – For focal spasticity or dystonia interfering with gait or care; blocks acetylcholine release at neuromuscular junction; effects last ~3 months; combined with therapy improves function. rarediseases.info.nih.gov

• Melatonin – For sleep dysregulation, which can lower seizure threshold; improves sleep onset/maintenance in many children; consult dosing by age/weight. rarediseases.info.nih.gov

• Proton-pump inhibitors / H2 blockers (if reflux aggravates sleep/aspiration risk) – Symptom-guided, short courses when needed; goal is comfort and aspiration prevention, not disease modification. rarediseases.info.nih.gov

• Polyethylene glycol or fiber agents – For constipation related to low mobility or meds; maintaining bowel regularity can reduce discomfort and behavior issues. rarediseases.info.nih.gov

(The above list reflects core, widely used options in pediatric neurogenetic epilepsies and spasticity. In every case, clinicians rely on FDA labels for seizure/spasticity indications and apply them to SCAR12 symptom profiles. There is no SCAR12-specific label.) rarediseases.info.nih.gov

---

Dietary molecular supplements

Note: Supplements support nutrition and comfort; they do not treat the gene defect. Use with clinician guidance, especially alongside antiseizure drugs.

1. Omega-3 fatty acids (DHA/EPA) – May support neuronal membrane health and have mild anti-inflammatory effects; often used to promote general brain and eye health; typical pediatric dosing is weight-based and individualized. rarediseases.info.nih.gov

2. Vitamin D – Important for bone health in low-mobility children and those on antiepileptics that affect bone turnover; dose to reach normal serum 25-OH D. rarediseases.info.nih.gov

3. Calcium – Pairs with vitamin D to protect bone density, especially when mobility is limited or valproate is used. rarediseases.info.nih.gov

4. Magnesium – Helps with constipation and sleep; excessive dosing can cause diarrhea; check interactions. rarediseases.info.nih.gov

5. Multivitamin with iron (when deficient) – Addresses diet gaps and iron-deficiency that can worsen fatigue and attention. rarediseases.info.nih.gov

6. Probiotics – May improve GI comfort and stool regularity; choose strains with pediatric safety data. rarediseases.info.nih.gov

7. Medium-chain triglyceride (MCT) oil – Convenient calories when intake is low; easy to add to purees; monitor for GI intolerance. rarediseases.info.nih.gov

8. Fiber supplements (inulin/psyllium) – Maintain bowel regularity with low mobility; titrate slowly with fluids. rarediseases.info.nih.gov

9. Coenzyme Q10 – Sometimes tried empirically in ataxias to support mitochondrial function though evidence is limited outside primary CoQ defects. PubMed+1

10. B-complex (including thiamine/folate/B12 when deficient) – Corrects documented deficiencies that can aggravate neuropathy or fatigue; test first. rarediseases.info.nih.gov

---

Immunity-booster / regenerative / stem-cell drugs

There are no approved “immunity boosters,” regenerative, or stem-cell drugs for SCAR12. Experimental regenerative strategies for recessive ataxias are preclinical/early-stage. Supportive medications below do not repair the gene but help symptoms so children can grow and learn.

• Baclofen – reduces spasticity so therapy is more effective; dose titrated; mechanism GABA-B agonism. rarediseases.info.nih.gov

• Tizanidine – spasticity relief to facilitate stretching and sleep; alpha-2 agonist. rarediseases.info.nih.gov

• Botulinum toxin – focal muscle overactivity reduction to prevent contractures; acetylcholine blockade at neuromuscular junction. rarediseases.info.nih.gov

• Melatonin – supports sleep consolidation, indirectly stabilizing seizure threshold; circadian receptor agonism. rarediseases.info.nih.gov

• CoQ10 (adjunct) – mitochondria cofactor; mixed evidence but sometimes tried for fatigue; electron transport chain support. PubMed+1

• Vitamin D – bone and immune modulation; reduces fracture risk with low mobility; nuclear receptor-mediated gene effects. rarediseases.info.nih.gov

---

Procedures / surgeries

1. Gastrostomy tube (G-tube) – Considered when unsafe swallowing or poor weight gain persists despite therapy; ensures safe nutrition/hydration and supports medication delivery. rarediseases.info.nih.gov

2. Orthopedic tendon-lengthening or contracture release – For fixed deformities that impair hygiene, seating, or walking after conservative care. Goal is comfort and easier caregiving. rarediseases.info.nih.gov

3. Intrathecal baclofen pump (ITB) – For severe, generalized spasticity not controlled by oral meds; delivers baclofen directly to the spinal fluid, reducing whole-body side effects. rarediseases.info.nih.gov

4. Vagus nerve stimulation (VNS) – Adjunct for drug-resistant epilepsy to reduce seizure frequency and intensity when multiple medications fail. rarediseases.info.nih.gov

5. Selective dorsal rhizotomy (rarely, highly selected) – In spasticity-dominant cases with preserved strength and therapy access; aims to reduce reflex overactivity to improve comfort and care. rarediseases.info.nih.gov

---

Preventions

• Vaccinations and infection control to reduce fever-triggered seizures and deconditioning. rarediseases.info.nih.gov

• Seizure action plan (home/school) with rescue meds to prevent injuries and prolonged events. rarediseases.info.nih.gov

• Home safety modifications (rails, non-slip mats) to prevent falls. rarediseases.info.nih.gov

• Regular therapy and stretching to prevent contractures and pressure injuries. rarediseases.info.nih.gov

• Adequate sleep to lower seizure risk. rarediseases.info.nih.gov

• Hydration and bowel routine to prevent constipation, discomfort, and agitation. rarediseases.info.nih.gov

• Sunlight/vitamin D and weight-bearing to protect bones. rarediseases.info.nih.gov

• Proper footwear and mobility aids to prevent falls. rarediseases.info.nih.gov

• Regular vision and dental care to prevent secondary issues that worsen function. rarediseases.info.nih.gov

• Genetic counseling for family planning (carrier testing, options). informatics.jax.org

---

When to see doctors

See the care team promptly for new or worsening seizures, repeated falls, feeding/choking episodes, weight loss, new weakness or contractures, sleep disruption affecting daytime function, or behavior/mood changes. Seek urgent help for prolonged seizures, breathing problems after a seizure, high-risk falls, or sudden severe headache/neck pain after trauma. Regular follow-ups track growth, nutrition, bone health, dental care, and therapy needs. rarediseases.info.nih.gov

---

Foods to prefer and to limit/avoid

Prefer:

• Soft, moist textures (yogurt, oatmeal, stews) for easier swallowing and energy density. rarediseases.info.nih.gov

• Lean proteins (eggs, fish, beans) to maintain muscle. rarediseases.info.nih.gov

• Healthy fats (olive oil, nut butters, avocado) to boost calories if intake is small. rarediseases.info.nih.gov

• High-fiber fruits/vegetables (bananas, mashed sweet potato) to support bowel regularity. rarediseases.info.nih.gov

• Whole grains (soft rice, quinoa) for steady energy. rarediseases.info.nih.gov

• Dairy/fortified alternatives for calcium and vitamin D. rarediseases.info.nih.gov

• Plenty of fluids (water, soups) to avoid dehydration-triggered seizures. rarediseases.info.nih.gov

• Small, frequent meals to maintain energy. rarediseases.info.nih.gov

• Omega-3 sources (fish, fortified foods) for general brain health. rarediseases.info.nih.gov

• Dietitian-guided supplements when intake is low. rarediseases.info.nih.gov

Limit/Avoid:

• Hard, crumbly, or dry foods that pose choking risk (dry crackers, nuts). rarediseases.info.nih.gov

• Very sticky foods (thick nut butter on bread) that are hard to clear. rarediseases.info.nih.gov

• Sugary drinks that displace nutrition and worsen dental risk. rarediseases.info.nih.gov

• Excess caffeine/energy drinks that can disturb sleep. rarediseases.info.nih.gov

• Ultra-processed salty snacks that worsen constipation and thirst. rarediseases.info.nih.gov

• Alcohol (adolescents/adults)—can lower seizure threshold and interact with meds. rarediseases.info.nih.gov

• Grapefruit juice if it interacts with specific meds your clinician flags. rarediseases.info.nih.gov

• Very large meals before sleep if reflux or aspiration risk exists. rarediseases.info.nih.gov

• Unsupervised “keto” or extreme diets—only use if a neurologist/dietitian prescribes for epilepsy. rarediseases.info.nih.gov

• Unverified supplements that may interact with antiseizure drugs. rarediseases.info.nih.gov

---

Frequently asked questions (FAQs)

1) Is SCAR12 the same as SCA12?
No. SCAR12 is autosomal recessive (often WWOX-related) with childhood onset and seizures; SCA12 is autosomal dominant (PPP2R2B repeat expansion) with adult-onset tremor/ataxia. informatics.jax.org+2rarediseases.info.nih.gov+2

2) What gene causes SCAR12?
Most reports link SCAR12 to WWOX; research continues on WWOX biology in brain development and stress pathways. informatics.jax.org+1

3) How is it diagnosed?
By clinical features (childhood ataxia ± seizures) and genetic testing confirming pathogenic biallelic variants. MRI may show mild cerebellar atrophy. rarediseases.info.nih.gov

4) Is there a cure?
Not yet. Care focuses on seizure control, therapy, nutrition, and safety while research explores underlying mechanisms in recessive ataxias. rarediseases.info.nih.gov

5) What is the outlook?
Course varies. Some children achieve assisted walking and communication with support; others have more significant disability. Early therapy and seizure control help function. rarediseases.info.nih.gov

6) Are there specific seizure medicines for SCAR12?
No SCAR12-specific drug exists; clinicians select broad-spectrum antiseizure medications matched to the child’s seizure types and tolerance. rarediseases.info.nih.gov

7) Does ketogenic diet help?
Ketogenic or modified Atkins diets can help certain epilepsies but must be specialist-supervised; evidence is not specific to SCAR12. rarediseases.info.nih.gov

8) Why genetic counseling?
Parents of an affected child are usually carriers; future pregnancies have a 25% risk. Siblings and relatives may want testing. informatics.jax.org

9) What’s different about WWOX?
WWOX participates in cell-stress response and neuronal survival; loss of function can cause early-onset neurodevelopmental syndromes with seizures and ataxia. informatics.jax.org+1

10) How is SCAR12 different from VPS13D-related ataxia?
VPS13D disorders are another recessive ataxia/spasticity spectrum; mechanisms center on mitochondrial dynamics/lipid transfer, not WWOX. PubMed+2ScienceDirect+2

11) Can ITB pumps or botulinum toxin help?
Yes, in selected cases with troublesome spasticity; they reduce muscle overactivity and improve comfort/therapy participation. rarediseases.info.nih.gov

12) Are there registries or trials?
Families can join natural-history cohorts for recessive ataxias and WWOX-related disorders to accelerate research and access studies as they emerge. ScienceDirect

13) Will my child lose skills over time?
Progression is variable; many children keep skills with ongoing therapy, seizure control, nutrition, and assistive technology. rarediseases.info.nih.gov

14) What schools should know?
Provide an IEP/504 plan, seizure action plan, mobility/feeding supports, and AAC as needed, so the child participates fully and safely. rarediseases.info.nih.gov

15) Where can I read more?
See summary pages from NIH GARD, MedGen/OMIM summary, Orphanet, and disease ontology resources that align on core features and inheritance. rarediseases.info.nih.gov+2ncbi.nlm.nih.gov+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 13, 2025.

PDF Documents For This Disease Condition References